The metabolic syndrome fluorishes in inactivity: Epidemiology, pathophysiology and implications for the hospital;Epidemiologie, pathofysiologie en implicaties voor de kliniek: Het metabool syndroom gedijt bij inactiviteit

Pharmaceutisch Weekblad

Volumn 138, Issue 45, 2003, Pages 1564-1567

  Van Wijk, J P H ^a   Rabelink, T J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; DYSLIPIDEMIA; GENETIC PREDISPOSITION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; RISK FACTOR;

EID: 0242712138     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 2001;88:38-42.
2. Meigs JB, D'Agostino RB Sr, et al. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997;46:1594-600.
3. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.
4. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
5. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108 suppl 6a:9S-14S.
6. Hartz AJ, Rupley DC Jr, Kalkhoff RD, et al. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. Prev Med 1983;12:351-7.
7. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
8. Després JP, Lemieux S, Lamarche B, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord 1995;19 suppl 1:S76-S86.
9. Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res 1998;6 suppl 1:8S-17S.
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
12. Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-66.
13. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:325-31.
14. Reynisdottir S, Ellerfeldt K, Wahrenberg H, et al. Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest 1994;93:2590-9.
15. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18-23.
16. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14:137-45.
17. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
18. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report. National Institutes of Health. Obes Res 1998;6 suppl 2:51S-209S.
19. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
20. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.